Common pathway signature in lung and liver fibrosis

ABSTRACT Fibrosis, a progressive accumulation of extracellular matrix components, encompasses a wide spectrum of distinct organs, and accounts for an increasing burden of morbidity and mortality worldwide. Despite the tremendous clinical impact, the mechanisms governing the fibrotic process are not yet understood, and to date, no clinically reliable therapies for fibrosis have been discovered. Here we applied Regeneration Intelligence, a new bioinformatics software suite for qualitative analysis of intracellular signaling pathway activation using transcriptomic data, to assess a network of molecular signaling in lung and liver fibrosis. In both tissues, our analysis detected major conserved signaling pathways strongly associated with fibrosis, suggesting that some of the pathways identified by our algorithm but not yet wet-lab validated as fibrogenesis related, may be attractive targets for future research. While the majority of significantly disrupted pathways were specific to histologically distinct organs, several pathways have been concurrently activated or downregulated among the hepatic and pulmonary fibrosis samples, providing new evidence of evolutionary conserved pathways that may be relevant as possible therapeutic targets. While future confirmatory studies are warranted to validate these observations, our platform proposes a promising new approach for detecting fibrosis-promoting pathways and tailoring the right therapy to prevent fibrogenesis.

[1]  H. Nakano,et al.  Rac, PAK and p38 regulate cell contact‐dependent nuclear translocation of myocardin‐related transcription factor , 2008, FEBS letters.

[2]  Ying E Zhang,et al.  Non-Smad pathways in TGF-β signaling , 2009, Cell Research.

[3]  J. V. van Laar,et al.  Interleukin-6 (IL-6) Trans Signaling Drives a STAT3-dependent Pathway That Leads to Hyperactive Transforming Growth Factor-β (TGF-β) Signaling Promoting SMAD3 Activation and Fibrosis via Gremlin Protein , 2014, The Journal of Biological Chemistry.

[4]  Nikolay M. Borisov,et al.  The OncoFinder algorithm for minimizing the errors introduced by the high-throughput methods of transcriptome analysis , 2014, Front. Mol. Biosci..

[5]  R. Wells The epithelial‐to‐mesenchymal transition in liver fibrosis: Here today, gone tomorrow? , 2010, Hepatology.

[6]  D. Lorrain,et al.  A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model , 2010, British journal of pharmacology.

[7]  A. Yoshimura,et al.  Protective role of JAK/STAT signaling against renal fibrosis in mice with unilateral ureteral obstruction. , 2014, Clinical immunology.

[8]  H. Chapman,et al.  Epithelial-mesenchymal interactions in pulmonary fibrosis. , 2011, Annual review of physiology.

[9]  N. Kaminski,et al.  Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis , 2006, The Journal of experimental medicine.

[10]  J. Gauldie,et al.  Dissecting fibrosis: therapeutic insights from the small-molecule toolbox , 2015, Nature Reviews Drug Discovery.

[11]  J. Iredale,et al.  Pathogenesis of liver fibrosis. , 1997, Clinical science.

[12]  E. Morrisey Wnt signaling and pulmonary fibrosis. , 2003, The American journal of pathology.

[13]  S. Dooley,et al.  Roles of TGF-beta in hepatic fibrosis. , 2002, Frontiers in bioscience : a journal and virtual library.

[14]  R. Derynck,et al.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling. , 2003, Nature.

[15]  G. Wolf,et al.  TGF-beta and fibrosis in different organs - molecular pathway imprints. , 2009, Biochimica et biophysica acta.

[16]  S. Janes,et al.  Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities , 2014, European Respiratory Journal.

[17]  X. Xiong,et al.  Organ fibrosis inhibited by blocking transforming growth factor-β signaling via peroxisome proliferator-activated receptor γ agonists. , 2012, Hepatobiliary & pancreatic diseases international : HBPD INT.

[18]  Anuh T. George,et al.  Blockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis , 2014, The Journal of Immunology.

[19]  A. Charonis,et al.  Integrin-linked kinase (ILK) in pulmonary fibrosis , 2010, Virchows Archiv.

[20]  Nikolay M. Borisov,et al.  Oncofinder, a new method for the analysis of intracellular signaling pathway activation using transcriptomic data , 2014, Front. Genet..

[21]  Nicolas Borisov,et al.  A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation , 2015, Oncotarget.

[22]  Oliver Eickelberg,et al.  The impact of TGF-β on lung fibrosis: from targeting to biomarkers. , 2012, Proceedings of the American Thoracic Society.

[23]  A. Mallat,et al.  The liver X receptor in hepatic stellate cells: a novel antifibrogenic target? , 2011, Journal of hepatology.

[24]  K. Hamaoka,et al.  Delayed inhibition of p38 mitogen-activated protein kinase ameliorates renal fibrosis in obstructive nephropathy. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  I. Hyodo,et al.  Involvement of integrin‐linked kinase in carbon tetrachloride–induced hepatic fibrosis in rats , 2006, Hepatology.

[26]  David A. Sass,et al.  Nonalcoholic Fatty Liver Disease: A Clinical Review , 2005, Digestive Diseases and Sciences.

[27]  A. Szabó,et al.  Fibrosis Related Inflammatory Mediators: Role of the IL-10 Cytokine Family , 2015, Mediators of inflammation.

[28]  S. Hubchak,et al.  Hypoxia-inducible factor-2α and TGF-β signaling interact to promote normoxic glomerular fibrogenesis. , 2013, American journal of physiology. Renal physiology.

[29]  Ying E. Zhang,et al.  Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.

[30]  G. Oster,et al.  Incidence and prevalence of idiopathic pulmonary fibrosis. , 2006, American journal of respiratory and critical care medicine.

[31]  S. Friedman,et al.  Scraping fibrosis: Expressway to the core of fibrosis , 2011, Nature Medicine.

[32]  G. Landreth,et al.  Peroxisome Proliferator-Activated Receptor Gamma Agonists , 2003 .

[33]  Cynthia Davidson,et al.  MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation. , 2012, American journal of respiratory cell and molecular biology.

[34]  S. Pyne,et al.  Role of sphingosine 1-phosphate and lysophosphatidic acid in fibrosis. , 2013, Biochimica et biophysica acta.

[35]  Lei Sun,et al.  New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis. , 2011, American journal of physiology. Lung cellular and molecular physiology.

[36]  R. Kalluri,et al.  Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. , 2013, American journal of physiology. Cell physiology.

[37]  A. Eddy Scraping fibrosis: UMODulating renal fibrosis , 2011, Nature Medicine.

[38]  K. Yamauchi,et al.  Co‐expression of TNFα and IL‐1β in human acute pulmonary fibrotic diseases: An immunohistochemical analysis , 1996 .

[39]  Alexander Aliper,et al.  Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs , 2015, Oncotarget.

[40]  Nikolay M. Borisov,et al.  Signaling pathways activation profiles make better markers of cancer than expression of individual genes , 2014, Oncotarget.

[41]  S. Murphy,et al.  Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease , 2014, Hepatology.

[42]  Anthony D. Schmitt,et al.  Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma , 2014, Hepatology.

[43]  S. Dedhar,et al.  Role of the integrin-linked kinase (ILK)/Rictor complex in TGFβ-1-induced epithelial–mesenchymal transition (EMT) , 2013, Oncogene.

[44]  Alexander M Aliper,et al.  Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients , 2015, Human Genome Variation.

[45]  M. Mori,et al.  Cytokines and STATs in Liver Fibrosis , 2012, Front. Physio..

[46]  K. Yamauchi,et al.  Co-expression of TNF alpha and IL-1 beta in human acute pulmonary fibrotic diseases: an immunohistochemical analysis. , 1996, Pathology international.

[47]  K. Wallace,et al.  Interleukin-1 participates in the progression from liver injury to fibrosis. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[48]  Xiang Zhao,et al.  Pathway-based Analysis Tools for Complex Diseases: A Review , 2014, Genom. Proteom. Bioinform..

[49]  Don C Rockey,et al.  Fibrosis--a common pathway to organ injury and failure. , 2015, The New England journal of medicine.

[50]  Nikolay M. Borisov,et al.  Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways , 2014, Oncotarget.

[51]  L. DiPietro,et al.  Apoptosis and angiogenesis: an evolving mechanism for fibrosis , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  P. Taylor,et al.  Interleukin-6 Signaling Drives Fibrosis in Unresolved Inflammation , 2014, Immunity.

[53]  Zhiyong Wu,et al.  Effect of the regulation of retinoid X receptor‐α gene expression on rat hepatic fibrosis , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

[54]  Atul J. Butte,et al.  Ten Years of Pathway Analysis: Current Approaches and Outstanding Challenges , 2012, PLoS Comput. Biol..

[55]  Y. Huang,et al.  Wnt signaling in liver fibrosis: progress, challenges and potential directions. , 2013, Biochimie.

[56]  Andrew Leask,et al.  TGF‐β signaling and the fibrotic response , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.